Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $33

Benzinga Newsdesk www.benzinga.com Positive 82.9%

Neg 0% Neu 0% Pos 82.9%

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $32 to $33.